Adma.O

ADMA Biologics maintains a conservative capital structure with total equity of $477.3 million against total liabilities of $146.9 million, resulting in a debt-to-equity ratio of 0.15. The company holds $87.6 million in cash and equivalents, which exceeds its long-term debt of $69.3 million, indicating a net cash position. Liquidity risk is assessed as low, supported by a current ratio implied by the balance sheet strength and operating cash flow of $50.4 million. The firm generates positive free cash flow after accounting for capital expenditures of $22.6 million, demonstrating operational self-sufficiency without immediate reliance on external financing.

Profitability metrics indicate strong operational efficiency, with a net income of $146.9 million on revenue of $510.2 million, yielding a net margin of approximately 28.8%. Return on equity stands at 34.6%, and return on assets is 26.5%, reflecting efficient use of its $624.2 million asset base. The company trades at a price-to-earnings ratio of 12.17 and an EV/EBITDA of 9.43, suggesting a valuation that may be attractive relative to growth potential, though cohort median comparisons are unavailable for precise benchmarking. The price-to-book ratio of 4.22 indicates the market values the company's tangible and intangible assets at a premium to book value.

Revenue concentration and segment details are not explicitly broken down in the available data, limiting specific analysis of product or geographic exposure. The total revenue of $510.2 million serves as the primary top-line metric, with gross profit of $292.8 million indicating a gross margin of approximately 57.4%. Without detailed segment data, the analysis assumes a consolidated operational model where the core biotechnology activities drive the majority of the financial performance.

Growth trajectory analysis is constrained by the absence of historical period data in the input. The current financial snapshot provides a single-period view, preventing the calculation of year-over-year revenue or earnings growth rates. Consequently, the assessment of momentum relies solely on the current period's profitability and cash flow generation, which appear robust given the high net income relative to revenue.

Risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt load and positive cash flow mitigate financial distress risks. However, the low classification confidence of 0.20 suggests potential ambiguity in the company's primary business activities or industry alignment, which could introduce uncertainty in peer comparisons and regulatory expectations.

Recent observations include analyst estimates with a mean price target of $17.00, significantly higher than the current market price of $8.46, implying potential upside according to market consensus. The mean recommendation of 2.20 leans towards a buy rating, with four buy ratings and one hold rating recorded. News events primarily reflect internal system reconciler activities rather than external corporate developments, indicating no major public disclosures or adverse news in the immediate observation window.

Revenue $114.5M, −0,3% YoY; Operating income +67,1% YoY.

• ▍Revenue $114.5M, −0,3% YoY
• ▍Operating income +67,1% YoY
• ▍Net income +68,5% YoY
• ▍Free cash flow +84,6% YoY
• ▍Net margin 39.6%

Revenue $139.2M, +18,4% YoY; Operating income +69,2% YoY.

• ▍Revenue $139.2M, +18,4% YoY
• ▍Operating income +69,2% YoY
• ▍Net income −55,9% YoY
• ▍Free cash flow −54,9% YoY
• ▍Net margin 35.5%

Revenue $134.2M, +12,0% YoY; Operating income +23,2% YoY.

• ▍Revenue $134.2M, +12,0% YoY
• ▍Operating income +23,2% YoY
• ▍Net income +1,4% YoY
• ▍Free cash flow −34,4% YoY
• ▍Net margin 27.1%

Revenue $122.0M, +13,8% YoY; Operating income +6,2% YoY.

• ▍Revenue $122.0M, +13,8% YoY
• ▍Operating income +6,2% YoY
• ▍Net income +6,7% YoY
• ▍Free cash flow +6,3% YoY
• ▍Net margin 28.1%

Revenue $114.8M; Operating income $34.9M.

• ▍Revenue $114.8M
• ▍Operating income $34.9M
• ▍Net margin 23.4%

Revenue $117.5M; Operating income $37.1M.

• ▍Revenue $117.5M
• ▍Operating income $37.1M
• ▍Net margin 95.2%

Revenue $119.8M; Operating income $39.6M.

• ▍Revenue $119.8M
• ▍Operating income $39.6M
• ▍Net margin 30.0%

Revenue $107.2M; Operating income $39.2M.

• ▍Revenue $107.2M
• ▍Operating income $39.2M
• ▍Net margin 29.9%

Revenue $510.2M, +19,6% YoY; Operating income +36,6% YoY.

• ▍Revenue $510.2M, +19,6% YoY
• ▍Operating income +36,6% YoY
• ▍Net income −25,7% YoY
• ▍Free cash flow −33,0% YoY
• ▍Net margin 28.8%

Revenue $426.5M, +65,2% YoY; Operating income +3 132,6% YoY.

• ▍Revenue $426.5M, +65,2% YoY
• ▍Operating income +3 132,6% YoY
• ▍Net income +800,0% YoY
• ▍Free cash flow +891,9% YoY
• ▍Net margin 46.4%

Revenue $258.2M, +67,6% YoY; Operating income +90,1% YoY.

• ▍Revenue $258.2M, +67,6% YoY
• ▍Operating income +90,1% YoY
• ▍Net income +57,1% YoY
• ▍Free cash flow +65,8% YoY
• ▍Net margin -10.9%

Revenue $154.1M, +90,4% YoY; Operating income +21,1% YoY.

• ▍Revenue $154.1M, +90,4% YoY
• ▍Operating income +21,1% YoY
• ▍Net income +8,0% YoY
• ▍Free cash flow +8,7% YoY
• ▍Net margin -42.8%